In a 70-year-old man who reports episodic flushing or heat rushes without a measurable rise in temperature, what is the most likely diagnosis?

Most Likely Diagnosis: Carcinoid Syndrome

In a 70-year-old man presenting with episodic flushing or "heat rushes" without measurable temperature elevation, carcinoid syndrome from a neuroendocrine tumor (NET) is a critical diagnosis to consider, though age-related hypogonadism and other causes must also be evaluated.

Primary Differential Considerations

The "dry flushing" (without sweating) described is characteristic of vasodilator-mediated conditions rather than sympathetic nervous system activation 1. In this age group, the key diagnoses include:

1. Carcinoid Syndrome (Most Important to Rule Out)

• Occurs in approximately 20% of patients with well-differentiated midgut NETs 2
• Presents with dry flushing in 70% of cases - flushing without sweating, often with palpitations 2
• May include diarrhea (50%), intermittent abdominal pain (40%), and sometimes lacrimation/rhinorrhoea 2
• Critical point: This is a potentially serious diagnosis requiring immediate workup 3, 1

2. Age-Related Hypogonadism ("Male Menopause")

• Common in 70-year-old men, particularly those with history of prostate treatment
• One case report 4 documented a 70-year-old man with carcinoid tumor who actually had post-orchiectomy climacteric flushing that resolved with diethylstilbestrol
• Hot flashes affect quality of life significantly and involve thermoregulatory dysfunction 5

3. Other Neuroendocrine Causes

• Pheochromocytoma (typically wet flushing with sweating)
• Medullary thyroid carcinoma
• VIPoma (though usually presents with profuse watery diarrhea) 2

Diagnostic Algorithm

Step 1: Characterize the Flushing Pattern

• Dry vs. wet: Absence of sweating suggests vasodilator-mediated (carcinoid, mastocytosis) rather than neural-mediated causes 1
• Associated symptoms: Ask specifically about:
  • Diarrhea, abdominal pain (suggests carcinoid) 2
  • Palpitations, severe hypertension episodes (suggests pheochromocytoma)
  • Urticaria, pruritus (suggests mastocytosis) 3
  • Sexual dysfunction, prior prostate treatment (suggests hypogonadism)

Step 2: Initial Laboratory Workup

Must obtain to exclude serious pathology 3, 6:

• 24-hour urine 5-HIAA (5-hydroxyindoleacetic acid) - elevated in carcinoid syndrome 2, 3
• Chromogranin A - marker for NETs 7
• Testosterone level - if hypogonadism suspected
• Thyroid function tests - exclude hyperthyroidism
• Plasma or 24-hour urine metanephrines - if pheochromocytoma suspected
• Serum tryptase - if mastocytosis suspected 3

Step 3: Risk Stratification

High-risk features requiring urgent evaluation 2, 3:

• Right-sided heart murmur (tricuspid regurgitation suggests carcinoid heart disease)
• Frequent flushing (>3 episodes/day) with 5-HIAA >300 mcmol/24h increases carcinoid heart disease risk 7
• Family history of NET syndromes or MEN1 2
• Abdominal mass or hepatomegaly

Step 4: Imaging if Biochemistry Positive

• CT or MRI abdomen/pelvis - look for primary NET (small bowel most common for carcinoid) 2
• Echocardiogram - if carcinoid syndrome confirmed, assess for valvular disease 7
• Octreotide scan (somatostatin receptor scintigraphy) - localizes NETs 7

Management Based on Diagnosis

If Carcinoid Syndrome Confirmed:

• Somatostatin analogues are first-line: Octreotide LAR 20-30 mg IM every 4 weeks or lanreotide 120 mg deep SC 7
• Short-acting octreotide 150-250 mcg SC three times daily for breakthrough symptoms 7
• Cardiology referral mandatory - 59% have tricuspid regurgitation 7
• Avoid triggers that precipitate carcinoid crisis (anesthesia, tumor manipulation) 2

If Hypogonadism:

• Testosterone replacement therapy if appropriate
• Manage expectations about symptom timeline

Critical Pitfalls to Avoid

1. Don't assume benign cause without workup - The case report 4 illustrates that even with confirmed carcinoid tumor, flushing may be from another cause, but you must prove this biochemically
2. Don't miss carcinoid heart disease - Check for murmurs and obtain echo if syndrome confirmed; this affects prognosis significantly 7
3. Don't delay somatostatin analogue therapy - Beyond symptom control, octreotide/lanreotide may control tumor growth (median time to progression 14.3 vs 6.0 months in PROMID trial) 7
4. Remember liver metastases are usually present - Carcinoid syndrome typically requires hepatic metastases to bypass first-pass metabolism 2

The distinction between serious neuroendocrine pathology and benign age-related changes hinges on systematic biochemical evaluation - clinical gestalt alone is insufficient 3, 6.